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Incidence and management of complications after neoadjuvant
chemotherapy followed by extrapleural pneumonectomy for
malignant pleural mesothelioma
Abstract
OBJECTIVE: To investigate the incidence and management of postoperative complications after
neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural
mesothelioma. METHODS: Patients with histologically proven mesothelioma of clinical stages T1-3,
N0-2, M0 and considered to be completely resectable received neoadjuvant chemotherapy
(cisplatin+gemcitabine or cisplatin+pemetrexed) followed by extrapleural pneumonectomy and
postoperative radiotherapy. The incidence and management of postoperative complications in general
and of bronchopleural fistula and postpneumonectomy-empyema in particular were analyzed. Univariate
analysis was performed to identify prognostic factors [sex, age, side of operation, weight loss, smoking,
chemotherapy, EORTC-score (European Organization for Research and Treatment of
Cancer-classification) and duration of operation]. RESULTS: Between 1st May 1999 and 15th August
2005, 63 patients underwent complete extrapleural pneumonectomy after neoadjuvant chemotherapy.
Postoperative complications were observed in 39 cases (62%) and 2 patients died within 30 days (3.2%).
Postpneumonectomy-empyema occurred in 15.8% of the patients (n=10), six with a bronchopleural
fistula on the right side. All empyemas were treated successfully. Five patients developed chylothorax
(7.9%) and four patients had complications due to a patch failure: cardiac herniation (n=2), restriction of
cardiac output (n=1) or gastric herniation (n=1). Patients with higher EORTC-score presented
significantly more postoperative complications (p=0.03). A longer duration of surgery tended to be
associated with a higher incidence of postoperative complications, especially of empyemas.
CONCLUSIONS: Extrapleural pneumonectomy after neoadjuvant chemotherapy can be performed with
mortality rates comparable to standard pneumonectomies. Complications are frequent but can be
successfully managed; the EORTC-score seems to be a predictor for postoperative complications.
DOI: 10.1016/j.ejcts.2006.01.015 
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Abstract
Objective: To investigate the incidence and management of postoperative complications after neoadjuvant chemotherapy followed by
extrapleural pneumonectomy for malignant pleural mesothelioma. Methods: Patients with histologically proven mesothelioma of clinical stages
T1—3, N0—2, M0 and considered to be completely resectable received neoadjuvant chemotherapy (cisplatin + gemcitabine or cisplatin + peme-
trexed) followed by extrapleural pneumonectomy and postoperative radiotherapy. The incidence and management of postoperative complica-
tions in general and of bronchopleural fistula and postpneumonectomy-empyema in particular were analyzed. Univariate analysis was performed
to identify prognostic factors [sex, age, side of operation, weight loss, smoking, chemotherapy, EORTC-score (European Organization for Research
and Treatment of Cancer-classification) and duration of operation]. Results: Between 1st May 1999 and 15th August 2005, 63 patients underwent
complete extrapleural pneumonectomy after neoadjuvant chemotherapy. Postoperative complications were observed in 39 cases (62%) and 2
patients died within 30 days (3.2%). Postpneumonectomy-empyema occurred in 15.8% of the patients (n = 10), six with a bronchopleural fistula on
the right side. All empyemas were treated successfully. Five patients developed chylothorax (7.9%) and four patients had complications due to a
patch failure: cardiac herniation (n = 2), restriction of cardiac output (n = 1) or gastric herniation (n = 1). Patients with higher EORTC-score
presented significantly more postoperative complications (p = 0.03). A longer duration of surgery tended to be associated with a higher incidence
of postoperative complications, especially of empyemas. Conclusions: Extrapleural pneumonectomy after neoadjuvant chemotherapy can be
performed with mortality rates comparable to standard pneumonectomies. Complications are frequent but can be successfully managed; the
EORTC-score seems to be a predictor for postoperative complications.
# 2006 Elsevier B.V. All rights reserved.
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It is suggested that the number of men dying each year
from malignant pleural mesothelioma (MPM) in Western
Europe will almost double over the next 20 years from 5000
in 1998 to about 9000 deaths per year around 2018 [1].
Without treatment, the majority of patients die within 12
months [2].
There is no generally accepted therapy for MPM.
Extrapleural pneumonectomy (EPP) is the most radical
surgical procedure and might offer long-term survival, if§ Presented at the joint 19th Annual Meeting of the European Association for
Cardio-thoracic Surgery and the 13th Annual Meeting of the European Society
of Thoracic Surgeons, Barcelona, Spain, September 25—28, 2005.
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ejcts.ctsnetjournDownloaded from used in a multimodality concept. In 1976, Butchart et al. [3]
reported about 29 patients undergoing EPP for diffuse MPM
with a very high perioperative mortality rate of 31%. In
current series, mortality after EPP without previous chemo-
or radiation therapy ranges from 4 to 15% [4—7]. However,
morbidity stays high with postoperative complication rates
around 60% [4,7].
With neoadjuvant chemotherapy, the incidence of post-
operative complications as well as the mortality rate was
expected to increase. However, our pilot study analyzing
neoadjuvant chemotherapy with cisplatin + gemcitabine
followed by EPP for MPM showed promising results [8] in
terms of feasibility and tolerability as well as median
survival, so that this concept was further investigated in our
institution. In the underlying study, the postoperative course
of a consecutive series of patients undergoing EPP after
neoadjuvant chemotherapy is analyzed in detail. by on April 28, 2009 als.org
I. Opitz et al. / European Journal of Cardio-thoracic Surgery 29 (2006) 579—5845802. Patients and methods
2.1. Patients and indications
Patients were eligible for a neoadjuvant concept if they
had a histologically confirmed diagnosis of MPM of any
histology, clinical stages T1—3, N0—2, M0 and if they were
considered to be completely resectable. Other inclusion
criteria were adequate health status (serum creatini-
ne < 150 mmol/l, predicted postoperative FEV1 > 1 l, ade-
quate cardiac function), Eastern Cooperative Oncology
Group (ECOG) performance status 0—2 [9], age older than
18 years, no prior pleurectomy or lung resection except for
diagnostic purposes and written informed consent. Patients
with contraindication for surgery, prior or coexisting
malignancies (except adequately treated in situ carcinoma
of the cervix or basal squamous cell carcinoma of the skin) or
with other serious illnesses (cardiac disease preventing
forced hydration or surgery, neurological or psychiatric
disorders, uncontrolled infection, severe liver disease or
uncontrolled diabetes) were excluded.
Patients were treated with neoadjuvant chemotherapy
using cisplatin + gemcitabine followed by EPP in a pilot study
[8] and after promising results, the Schweizer Arbeitsge-
meinschaft fu¨r Klinische Krebsforschung (SAKK) performed a
nationwide, multicentre phase II trial [10]. Currently,
patients receive cisplatin + pemetrexed as neoadjuvant
chemotherapy before EPP.
2.2. Interventions
Neoadjuvant chemotherapy consisted of three cycles of
cisplatin 80 mg/m2 on day 1 and gemcitabine 1000 mg/m2 on
days 1, 8 and 15 administered every 28 days or, since March
2003, of cisplatin 80 mg/m2 on day 1 and pemetrexed
500 mg/m2 on day 1 administered every 21 days. Tumour
response was assessed by computed tomography (CT) using
unidimensional measurement of the pleural thickness
perpendicular to the chest wall and guidelines according
to the modified Response Evaluation Criteria in Solid Tumours
(RECIST) [11]. Patients were considered to be resectable
when there were no obvious signs for widespread chest wall
invasion (resectable chest wall lesions were accepted) or
obvious infiltration of mediastinal structures as the aorta,
heart, spine or oesophagus according to the CT scan
performed after neoadjuvant chemotherapy. Surgery was
performed within 6 weeks after completion of the last
injection of chemotherapy (day 15 of the third cycle). The
procedure included a complete EPP with resection of the
ipsilateral pericardium and the ipsilateral diaphragm. It was
performed via extended anterolateral thoracotomy through-
out the bed of the 6th rib, which was occasionally resected. If
resection in the posterior costodiaphragmatical angle was
difficult, a second lateral thoracotomy two intercostal spaces
lower was carried out. Previous trocar sites for thoracoscopic
biopsy were excised. Dissection plane of EPP was between
parietal pleura and endothoracic fascia. The mediastinal
pleura was bluntly dissected down towards the hilar
structures, and the pericardium was opened widely. Vessels
and main bronchus were closed using stapling devices.
Radical mediastinal lymphadenectomy was performed. Theejcts.ctsnetjourDownloaded from diaphragmwas completely resected at its insertion site at the
thoracic wall without opening of the peritoneum. It was
reconstructed with a Mersilene mesh (Mersilene; Ethicon,
Inc, Sommerville, NJ, USA). Equine xenopericard patch
(Supple Peri-guard Synovis Surgical Innovations; St Paul, MN,
USA) was used for pericardium reconstruction. If localized
chest wall infiltration occurred, this region was excised en
bloc with the pleuropneumonectomy specimen. Patients with
multilevel thoracic wall invasion were excluded from radical
resection and herewith from analysis. Final pathological
staging was carried out following the TNM staging system
[12]. Radiotherapy was performed according to definite
tumour stage (histologically confirmed local infiltration
beyond the endothoracic fascia) and if high-risk zone of
resection was defined by the operating surgeon. Patients
received three-dimensional conformal radiotherapy using a
6-MV linear accelerator equipped with a multileaf collimator.
If multilevel high-risk situation of residual disease was given,
a radiation dose of 30 Gy to the ipsilateral hemithorax and a
boost dose of 20 Gy to the area of highest risk was performed
(fractionation schedule 2 Gy/day, five times a week).
Radiation treatment was delivered with two equally
weighted, opposed anterioposterior—posterioanterior fields,
and critical organ structures were shielded with multileaf
collimators. Patients with a single high-risk area received
involved-field radiotherapy of 45—60 Gy (fractionation 1.8—
2 Gy/day, five times a week).
Since May 2005, five patients were treated with intensity-
modulated radiotherapy receiving in clinical target volume 1
(=field of surgery including the entire preoperative pleural
and pulmonary structures) 45—46 Gy and in clinical target
volume 2 (=risk of residual postoperative microscopic disease
or the area of highest risk for intrathoracic relapse) a total
dose of 55.9—56.2 Gy.
2.3. Analysis of data
All consecutive patients who underwent EPP after
neoadjuvant chemotherapy in our centre were retrospec-
tively analyzed for the incidence and management of
postoperative complications. Postoperative complications
within the hospital stay were defined as complications
directly related to surgery such as major bleeding with
necessity of revision, bronchopleural fistula, postpneumo-
nectomy-empyema, patch failure, chylothorax or as general
complications including adult respiratory distress syndrome
(ARDS), pneumonia, atrial fibrillation (AF), myocardial
infarction, deep vein thrombosis or pulmonary embolism.
Vocal cord paralysis, Horner syndrome and seroma were
documented. The retrospective data were collected from
medical records archived in our data management program
KISIM Version 4.785.
Statistical analysis was carried out using the software
package SPSS for Windows, version 11, SPSS Inc. Data are
given in total number and percentages. Binary logistic
regression analysis and if possible multivariate analysis was
performed in order to define odds ratios and 95% confidence
interval for the incidence of postoperative complications,
bronchopleural fistula and postpneumonectomy-empyema.
The prognostic factors analyzed were sex, age, side of
operation, weight loss, smoking, exposure to asbestos, by on April 28, 2009 nals.org
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cisplatin + pemetrexed), EORTC-score (European Organiza-
tion for Research and Treatment of Cancer-classification) and
duration of surgery. The EORTC-score was calculated as
follows [13]: (0.55)a + (0.6)b + (0.52)c + (0.67)d + (0.6)e(a) ifTable
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(e) if male gender.Between 1st May 1999 and 15th August 2005, 63 patients
(92% male) underwent EPP after completion of three cycles
neoadjuvant chemotherapy (39 on the right and 24 on the
left side). The median age was 57 years (37; 69) at the time
of surgery. Fifty-one patients (81%) were symptomatic in
terms of dyspnoea, 30 patients (48%) suffered from chest
pain and weight loss (more than 10% bodyweight) occurred
in 25 cases (40%). Asbestos exposure was identified in
43 patients (68%) and 27 patients (42%) presented a history
of more than 10 pack years smoking. Patient’s characteristics
are listed in Table 1.
Diagnosis was confirmed in 58 patients (92%) via thoraco-
scopy, the remaining five patients underwent a small thora-
cotomy. In 36 cases (57%), talc pleurodesis was performed
during the same intervention. Mediastinal lymph node status
was assessed via mediastinoscopy in 51 patients (81%) and
8 patients were staged N2 after mediastinoscopy.
After staging procedures, 47 patients (75%) received three
cycles of the combination cisplatin + gemcitabine as neoad-
juvant chemotherapy and, since March 2003, 16 patients
(25%) received the combination cisplatin + pemetrexed. Side
effects were observed in 68% of the cases (n = 43), whereas
nausea or emesis (n = 27) were the most frequent, followed
by neurological (n = 13) and haematological (n = 7) complica-
tions. In the subsequent CT scan, progressive disease was
diagnosed in 11 patients (17%), in 32 cases (51%) no change
was observed and in 20 patients (32%) partial response could
be determined.1
nt’s characteristics
Number of patients (%)
-PS
36 (57)
21 (33)
6 (10)
stage
1 9
2 36
3 18
4
0 43
1 9
2 11
logy
itheloid 44
xed 17
rcomatoid 2
-PS: The Eastern Cooperative Oncology Group-Performance Status.
ejcts.ctsnetjournDownloaded from 3. Results
Between 1st May 1999 and 15th August 2005, 63 patients
(92%male) underwent EPPafter completion of three cycles of
neoadjuvant chemotherapy. It was performed in a median
operation time of 355 min (240—490 min). Intraoperative
complications occurred in seven cases (11%): two injuries of
the spleen capsule requiring splenectomy in one case. Three
patients presented abnormal bleeding tendency during
operation leading in one case to perioperative transfusion
of five erythrocyte concentrates and four fresh frozen
plasmas. Two patients suffered from intraoperative cardiac
arrhythmia.
The median cumulative ICU stay was 4 days (1—31 days),
whereas patients stayed on average 1.5 times (SD 0.9) in ICU.
The median duration of hospital stay was 15 days (6—39
days). Two patients died in hospital or within the first 30 days
after operation (in-hospital- and 30-days mortality 3.2%).
One patient (obese with a diabetes mellitus) succumbed to
septic multiorgan failure due to pneumonia on the seventh
postoperative day and the other patient died from a
pulmonary embolism at day 4.
Postoperative complications related to the operation
occurred in 39 cases (62%) (Fig. 1). Surgery-related
complications occurred in 22 patients (35%): 5 patients
(7.9%) presented a chylothorax, 2 of which had to be
reoperated for surgical closure of thoracic duct. The other
three patients were successfully treated with parenteral
alimentation. Ten patients (15.8%) developed postpneumo-
nectomy-empyema, all except for three on the right side. In
six cases, bronchopleural fistula was diagnosed without
exception after right-sided EPP. These patients with post-
pneumonectomy-empyema required reoperation with radi-
cal debridement and packing of the pleural cavity with
povidone—iodine-soaked towels (dilution 1:10). This proce-
dure was repeated in 2-day intervals until macroscopical
disappearance of the infection. In case of proven bronch-
opleural fistula, omentoplasty was performed in two cases
and muscle flap technique in four cases (three times serratus
anterior muscle, once latissimus dorsi muscle). Finally, the
pleural space was obliterated with antibiotic solution (1 l
NaCl 0.9% mixed with 2.2 g amoxicilline/clavulanic acid,
0.3 g netilmicin and 1 g vancomycin) as described previously
[14]. With this concept, we were able to manage successfully
all empyemas and the chest was closed within 8 days.Fig. 1. Surgery related postoperative complications. BPF: bronchopleural
fistula. Data are given in percentage.
 by on April 28, 2009 als.org
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Fig. 2. General postoperative complications. AF: atrial fibrillation, PE: pul-
monary embolism, ARDS: adult respiratory distress syndrome. Data are given in
percentage.Other surgery-related complications were cardiac hernia-
tion (n = 2) due to dehiscence of the patch or restriction of
cardiac output due to constrictive patch (n = 1) and gastric
herniation after dehiscence of the diaphragmatic recon-
struction (n = 1). Altogether, 19 patients had to be reoper-
ated for surgical complications (30.2%), 3 of them because of
bleeding complications. Submuscular seromas were observed
in 11 cases (17.5%). Horner syndrome (n = 5) and vocal cord
paralysis (n = 2) were sequellaes of radical resection because
of direct involvement of the nerve.
Themost frequent complication was atrial fibrillation with
23 cases (37%). Twenty-two patients received amiodarone
(cordarone) medication for successful medical conversion of
heart-rhythm, one patient converted spontaneously. One
patient developed ARDS 2 days after operation but fully
recovered after prolonged intubation. Other complications
are summarized in Fig. 2.
Univariate analysis of the incidence of postoperative
complications, bronchopleural fistula- and postpneumo-
nectomy-empyema rate showed that neither age, weight
loss, smoking, asbestos exposure, chemotherapy (cispla-
tin + gemcitabine vs cisplatin + pemetrexed) nor side of
operation were significantly influencing factors (Table 2).
The EORTC-score showed a significant impact on the
incidence of postoperative complications: per 1 point
increase in EORTC-score, the incidence increased by factor
4.5 ( p = 0.03). A tendency that women developed less
complications than men ( p = 0.08) was observed but this
effect is questionable because of the low number of women
in the sample size (n = 5). Likewise the duration of operation
as a continuous variable tended to significantly influence
the incidence of postoperative complications ( p = 0.07),
which was equally observed for the incidence of post-Table 2
Prognostic factors for the incidence of postoperative complications
OR 95% CI p
Sex (female vs male) 0.1 0.01; 1.3 0.08
Age at diagnosis 0.9 0.9; 1.1 ns
Side of operation (left vs right) 0.4 0.2; 1.3 ns
Weight loss (yes vs no) 0.7 0.2; 1.9 ns
Smoking (yes vs no) 1.1 0.4; 3.1 ns
Chemotherapy (cisplatin + pemetrexed vs
cisplatin + gemcitabine)
0.4 0.1; 1.7 ns
Duration of operation 1 0.99; 1.01 0.07
EORTC-prognostic score 4.5 1.2; 17.3 0.03
EORTC-score: European Organization for Research and Treatment of Cancer-
classification. p-value < 0.05 were statistically significant. OR: odds ratio, 95%
CI: confidence interval.
ejcts.ctsnetjourDownloaded from pneumonectomy-empyema ( p = 0.07). This effect was not
observed for patients developing BPF. BPF always occurred
after right-sided pneumonectomies. It was striking that all
six patients received the combination cisplatin plus
gemcitabine, but the numbers in the cisplatin—pemetrexed
treated patients might be too small.4. Discussion
These data report our experience with 63 cases of EPP
performed after induction chemotherapy. The results
demonstrate that the mortality rate of 3.2% is relatively
low and compares favourably to series of EPP without
previous neoadjuvant chemotherapy. The mortality rate is
lower than after pneumonectomy alone with, e.g. 6.2% in a
large multicentre, prospective series of 569 pneumonec-
tomies from the Lung Cancer Study Group [15]. Postoperative
morbidity remains high with 62% but is comparable to other
centres’ complication rate with 60.4% reporting about 328
EPP for MPM without induction chemotherapy in a time
period of 20 years [4]. Also, mortality in this series after
application of adjuvant chemotherapy with rates of 3.4% is
comparable to our results after neoadjuvant chemotherapy.
The relatively low mortality rate in comparison to a high
morbidity rate shows that complications can be managed in a
multidisciplinary approach.
Overall postpneumonectomy-empyema rate was 15.8%
and the most serious postoperative complication. It was
caused in 60% by bronchopleural fistulas on the right side. The
fact that the last empyema occurred in February 2002 seems
to confirm that our preventive concept of irrigation of the
thoracic cavity with a povidone—iodine solution diluted 1:10
with NaCl 0.9% at the end of the operation might be
important. Perioperative prophylactic antibiotic regimen
with amoxicillin for 5 days was applied routinely in all
patients. Sugarbaker et al. [4] even used prophylactic triple
intravenous chemotherapy for 5 days with cefazolin,
levofloxacin and metronidazole for reasons of the prosthetic
material used.
The rate of bronchopleural fistula (9.5 %) seems to be very
high in comparison to the literature (2.4%; 6.7%) [4,7], and
might be associated in our series with the concept of
neoadjuvant chemotherapy. It is well documented that in an
analogous manner, patients with lung cancer present
increased morbidity and mortality after neoadjuvant
chemotherapy [12]. An important factor for prophylaxis is
a short bronchial stump in order to prevent blind end for
secretion retention. Thiswas aimed in all our procedures and
a long stump was never the reason for the fistula. The other
important point is avoidance of devascularization during
preparation. This is difficult to respect during EPP since the
radicality of the procedure together with mediastinal lymph
node dissection automatically causes some sort of devascu-
larization. Some groups routinely cover the bronchial stump
with a parathymic-pericardial fat pad based on a proximal
pedicle and fixed with a suture [4]. To our experience
coverage of the bronchial stumpwith vascularized intrathor-
acic tissue is difficult particularly on the right side for
reasons of lacking material when radical resection was
performed. The only possible prophylactic coverage needs by on April 28, 2009 nals.org
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perform this routinely as a prophylaxis since it would
increase the surgical trauma unnecessarily in 90% of the
patients. Additionally, we observed that patients with MPM
have very often only thin intercostal muscles due to the
underlying disease that is associated with kachexy. Further-
more, we have experienced that a postpneumonectomy-
empyema even in the presence of BPF can be treated
successfully.
Another reason might be drainage duration of the thoracic
cavity, which remains a point of discussion. As the 24—28
Charrie`re tube serves as a monitor for bleeding, we remove it
within the first 48 h the latest. Clampage is performed and
opened once every 8 h for investigation of bleeding or for
compensation of mediastinal shift in cases of excessive fluid
production. Other groups insist on leaving in the drain for
approximately 3 days allowing removal of fluid of the operated
hemithorax for balancing the chest [4,7]. On the other side,
the drain can be a potential danger for contamination along
the drain to the inside of the thoracic cavity.
But not only prophylaxis, management of bronchopleural
fistula and postpneumonectomy-empyema also varies among
different centres ranging from bronchoscopical sealing of
small fistulas, open closure of the bronchial stump, debride-
ment of the pleural cavity to tube thoracostomy alone, Clagett
window, obliteration of the pleural space with antibiotic
solution (Clagett procedure) [16] or vascularized tissueoreven
thoracoplasty [17] with success rates up to 90%. Our closed
chest management with stepwise radical debridement of the
pleural cavity and packing with povidone—iodine-soaked
dressings plus coverage of the bronchial stump if broncho-
pleural fistula, and finally, instillation of antibiotic solution
[14] was 100% successful in terms of mortality and control of
infection. This might be due to aggressive resection of the
necrotic tissue in a standardized and repeated manner
allowing consequent purgation of the pleural space. We were
not obliged to remove the pericardial patch or the mersilene
mesh for diaphragmatic reconstruction.
The second most common surgical complication was
chylothoraxwith 7.9%of the patients,whichwas also observed
by other groups in a relatively high percentage (6.7%) [7]. This
is probablyduetoaggressive resectionalong the thoracic aorta
and the inferior mediastinum. A prophylactic measure can be
clipping of the lymphatic vessels to assure lymphostasis or
ligating the thoracic duct near the diaphragm. However, the
lymph vessels are often not identifiable during surgery. If
chylothorax occurs, conservative treatment with parenteral
nutrition is the first step. When chylus secretion exceeds
500 ml after 5 days, reoperation is recommended [18]. We
performed open closure of the thoracic duct in all cases of
revision. If the leakage cannot be identified, mass ligature of
the tissues containing the thoracic duct above the diaphragm
or below the aortic arch is recommended [19]. We always
packed the thoracic cavity with povidone—iodine soaked
dressings at the end of the reoperation. They were removed
after 48 h with the intention to prevent empyema and to
enable us to ensure sealing.
Failure of the pericardial-patch occurred in 4.7%. The
patients suffered from cardiac herniation in two cases within
the first hours after operation. In one case, persistent
orthostatic hypotension was caused by a too tightly suturedejcts.ctsnetjournDownloaded from patch and became finally apparent 15 days postoperatively.
These complications are fully avoidable with the appropriate
surgical technique. It is recommended to start the sutures of
the pericardial patch in the deepest andmost difficult part and
toensure that the stitchesare set in the remainingpericardium
and not in the loose tissue of the posterior mediastinum.
Another complication related to technical problems was a
gastric herniation due to dehiscence of the diaphragmatic
patch. This complication rate of 1.7% is particularly lower than
reported in the literature (8.1%) [7] although we perform
complete resection of the diaphragm for radicality reason. It is
recommended to leave a rim of the diaphragmatic crus around
the oesophagus for stability at the hiatus, but there are no
oncologic data supporting one or other technique [4]. Since
this event, all marlex meshes were fixed with stitches around
all the ribs, which avoided another herniation.
Bleeding complications became rare with the routine
application of argon beamer technique for haemostasis and is
comparable to the one reported in the literature [7].
Non-technical complications were atrial fibrillation (AF) in
most cases. The reported percentage of 37% is comparable to
AF rates observed by other groups (17%, 24% and 44%)
[4,7,20]. In a multivariate analysis of patients undergoing
thoracic surgery, significant variables for the incidence of
atrial fibrillation were male sex, age over 50 years,
congestive heart failure, history of arrhythmias and history
of peripheral vascular disease [21]. But nevertheless,
prophylactic strategies are currently not recommended.
In conclusion, EPP after neoadjuvant chemotherapy can
be performed with a low mortality but complications are still
frequent even if they can be successfully managed. This
relatively high incidence of complications reflects the
magnitude of this procedure. It was obvious for us that
there is a learning curve although not provable in this data
analysis. By an increasing number of operations performed by
the same team, many of the complications are either
avoidable or treatable in a very early phase. An interesting
approach would be anticipation of the known complications;
therefore, we wanted to perform a multivariate regression
analysis in order to define independent prognostic factors.
Surprisingly, age does not significantly influence the
incidence of postoperative complications. The side of
operation did not influence the overall complication rate
although bronchopleural fistula was observed only after
right-sided EPP ( p = 0.07). According to our results, the
EORTC-score seems to be a prognostic factor for prediction of
postoperative complications. However, this factor was
demonstrated to be the only influencing one, so that
multivariate analysis was not performed. This might be
feasible in the future with a higher number of patients so that
independent factors for postoperative complications may be
defined. Inclusion of this knowledge in the algorithm of
decision for EPP indication might help in selecting patients
and therefore improve short-term outcome.
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Mr B. Keogh (Birmingham, United Kingdom): You have shown a very good
mortality rate, but it seems as though the price that you pay for that is a
significant amount of postoperative morbidity. Do you have an obvious and easy
explanation for the high incidence of empyemas?
Dr Opitz: Dr Sugarbaker reported in the postgraduate course an empyema
rate of 3% only. It might be possible that our empyema rate is higher due to the
fact that patients received neoadjuvant chemotherapy. And as to date we have
the largest series of patients undergoing neoadjuvant chemotherapy followed
by extrapleural pneumonectomy, we don’t have any comparison.
Dr M. Orringer (Ann Arbor, USA): There still remains controversy on the
other side of thewater if thismajor undertaking is justified inmost patients with
mesothelioma.DespiteDavid Sugarbaker’s enthusiasmand the tremendouswork
that he and you and your colleagues have done in this area, this is an enormous
price topay for a disease that formost of ourpatients translates to12—14months
of survival. A right-sided empyema and bronchopleural fistula is just a horr-
endous complication for somebody to put up with in the last months of life.
You say that the bronchopleural fistula was managed. How about the
empyema?Did theyhaveanopenwindow(Eloesserprocedure)?Did theyhave the
chest closed and filledwith antibiotics (Clagett procedure)? Did the patients and
their families spend the rest of their time caring for a huge open chest wound?
What would the survival have been had the patients received only chemoradia-
tion therapy and no resection? Would it have been any less traumatic for the
patient? Again, I compliment you on a tremendous paper. Thank you very much.
Dr Opitz: As to your first comment concerning morbidity, we agree,
morbidity rates of 60% are high. But taking into account the overall results of
our multicenter national study, we observed that quality of life within the first
3 months after operation did not deteriorate. Despite the reported morbidity,
the procedure is justified since most complications can be treated successfully
and quality of life is re-established. The median survival time is almost 2 years
and better than reported in any series. Concerning your question to the
empyema, we did not perform any Clagett window. We apply a radical
debridement in 2-day intervals and fill the pleural cavity with povidone—iodine
soaked dressings. This procedure is repeated three times and the thoracic
cavity is finally closed after filling with an antibiotic solution. With this
treatment, we were able to control infection in every case.
Dr J. Benfield (Los Angeles, USA): I would like to follow up on Dr Orringer’s
comment about quality of life. In my experience with patients with malignant
mesotheliomas, they unfortunately have a miserable quality of life despite
everything we do and try. I noted in your presentation that you had a significant
incidence of objective remission based on the induction chemotherapy. This
suggests the possibility that chemotherapy might eventually become primary
therapy with resection as adjunctive treatment. Do you and your colleagues
think there is a place, or perhaps there will be a place, for random prospective
studies of nonoperative therapy (with operation as an adjunct, if needed)
versus induction therapy plus extrapleural pneumonectomy?
Dr Opitz: We don’t have plans for that at the moment, no.
Dr Benfield: I gather you don’t anticipate that there will be a place for that
in the future. Let me be on record to say that I think there will be a place for
that in the future.
Dr G. Leschber (Berlin, Germany): Dr Sugarbaker yesterday told us that he
always covers this stump with some tissue. What is your experience? Do you
have any strategy to cover the right-sided stump, bronchial stump?
Dr Opitz: After radical extrapleural pneumonectomy we never find local
viable tissue to cover the bronchial stump. An intercostal muscle flap after EPP
is often thin. Other groups cover the stump with an extrathoracic muscle flap
or with aomentoplasty. But we do not perform this since it would be
unnecessary in 80%.
Dr B. Passlick (Freiburg, Germany): I think that this is the largest series of
patients who were treated neoadjuvantly with this disease. So I would like to
know what was the tumor response to the neo-adjuvant treatment? Do you
have any data on the histological specimen of the primary tumor and also on
the lymph nodes? Was there any tumor regression or was it without any
reaction after the neoadjuvant treatment?
Dr Opitz: Themajority of tumor specimen show a response of less than 10%
necrosis and only in 5% the tumor is necrotic in up to 90%.
Dr W. Weder (Zurich, Switzerland): I would like to answer to Dr Benfield
that there is a randomized trial activated in England which is called the MARS
trial, and investigate the role of surgery after induction chemotherapy in a
randomized fashion. by on April 28, 2009 nals.org
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